Other
Melanotan II
Melanotan II (MT-II)
Synthetic α-MSH analog · originally developed for melanoma prevention
- FDA Status
- Not FDA-approved · Banned in EU as research chemical
- Class
- Cyclic heptapeptide · α-MSH analog
- Sequence
- Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2
- Half-life
- ~30 min · effect cumulative
Mechanism of action
- Melanocortin receptor agonism (MC1R, MC3R, MC4R)
- MC1R → melanin synthesis (skin darkening)
- MC4R → appetite suppression and erectile function
- Non-selective receptor profile drives side effects
Research areas
- Erythropoietic protoporphyria (parent compound afamelanotide is approved)
- UV-induced skin damage protection (theoretical)
- Erectile dysfunction (off-label)
- Appetite/body weight (rarely sustained)
Evidence and clinical data
Parent compound afamelanotide (Scenesse) is FDA-approved for EPP. MT-II itself remains research chemical. Significant tachyphylaxis with continued use.
Safety profile
Concerning AE profile: spontaneous erections, severe nausea, blood pressure changes, melanoma risk concerns from rapid mole growth. Several deaths reported with contaminated supply.
Why this peptide is trending in 2026: Tan-enhancement community demand. NOT recommended due to AE profile. Listed for completeness only.
Educational use only. PeptideAdvance does not sell Melanotan II, recommend its use, or provide medical advice. The information above is a summary of published research and regulatory status as of April 2026. Some peptides discussed here are not FDA-approved or are restricted under FDA Category 2 — their use outside of authorized clinical research may carry legal and safety implications. Always consult a licensed healthcare professional.